MA53858A - Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques - Google Patents
Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiquesInfo
- Publication number
- MA53858A MA53858A MA053858A MA53858A MA53858A MA 53858 A MA53858 A MA 53858A MA 053858 A MA053858 A MA 053858A MA 53858 A MA53858 A MA 53858A MA 53858 A MA53858 A MA 53858A
- Authority
- MA
- Morocco
- Prior art keywords
- alphavirus
- delivery
- biotherapeutic agents
- based replicons
- replicons
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862742868P | 2018-10-08 | 2018-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53858A true MA53858A (fr) | 2021-09-15 |
Family
ID=68343515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053858A MA53858A (fr) | 2018-10-08 | 2019-10-08 | Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques |
Country Status (17)
Country | Link |
---|---|
US (1) | US20200109178A1 (fr) |
EP (1) | EP3864027A1 (fr) |
JP (1) | JP2022512625A (fr) |
KR (1) | KR20210074314A (fr) |
CN (1) | CN113227122A (fr) |
AU (1) | AU2019359204A1 (fr) |
BR (1) | BR112021006614A2 (fr) |
CA (1) | CA3115480A1 (fr) |
CL (1) | CL2021000855A1 (fr) |
CO (1) | CO2021006453A2 (fr) |
EA (1) | EA202190907A1 (fr) |
IL (1) | IL282043A (fr) |
MA (1) | MA53858A (fr) |
MX (1) | MX2021004032A (fr) |
PH (1) | PH12021550759A1 (fr) |
SG (1) | SG11202103167VA (fr) |
WO (1) | WO2020076775A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
TWI828168B (zh) * | 2019-06-20 | 2024-01-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 |
US20210347828A1 (en) | 2020-05-11 | 2021-11-11 | Janssen Pharmaceuticals, Inc. | RNA Replicon Encoding a Stabilized Corona Virus Spike Protein |
IL309889A (en) * | 2021-07-09 | 2024-03-01 | Replicate Bioscience Inc | EASTERN EQUINE encephalitis viruses, self-replicating RNA structures and their uses |
CN113846113B (zh) * | 2021-09-09 | 2022-09-13 | 臻赫医药(杭州)有限公司 | 一种有限自我复制mRNA分子系统、制备方法及应用 |
CN114317563B (zh) * | 2021-12-17 | 2023-09-05 | 华南理工大学 | 提高基因表达的rna复制子及其应用 |
CN116179603A (zh) * | 2022-09-30 | 2023-05-30 | 中国科学院深圳先进技术研究院 | 稳定表达外源基因的sinv载体及其制备方法和应用 |
CN118147171A (zh) * | 2024-03-08 | 2024-06-07 | 上海复诺健生物科技有限公司 | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 |
CN118086395B (zh) * | 2024-04-25 | 2024-06-21 | 南京农业大学三亚研究院 | 一种盖塔病毒质粒载体、弱毒株及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002303330B2 (en) * | 2001-05-31 | 2008-07-24 | Novartis Vaccines And Diagnostics, Inc. | Chimeric alphavirus replicon particles |
WO2006078294A2 (fr) * | 2004-05-21 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Vecteurs d'alphavirus pour vaccins contre pathogenes respiratoires |
WO2013177133A2 (fr) * | 2012-05-21 | 2013-11-28 | The Regents Of The Univerisity Of California | Génération de cellules ips humaines par un arn de synthèse auto-réplicatif |
JP7382230B2 (ja) * | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組み換えウイルスレプリコン系及びその使用 |
-
2019
- 2019-10-08 MA MA053858A patent/MA53858A/fr unknown
- 2019-10-08 SG SG11202103167VA patent/SG11202103167VA/en unknown
- 2019-10-08 JP JP2021518944A patent/JP2022512625A/ja active Pending
- 2019-10-08 CN CN201980079187.XA patent/CN113227122A/zh active Pending
- 2019-10-08 KR KR1020217013479A patent/KR20210074314A/ko unknown
- 2019-10-08 EP EP19794362.4A patent/EP3864027A1/fr active Pending
- 2019-10-08 MX MX2021004032A patent/MX2021004032A/es unknown
- 2019-10-08 US US16/595,980 patent/US20200109178A1/en active Pending
- 2019-10-08 EA EA202190907A patent/EA202190907A1/ru unknown
- 2019-10-08 BR BR112021006614-4A patent/BR112021006614A2/pt unknown
- 2019-10-08 CA CA3115480A patent/CA3115480A1/fr active Pending
- 2019-10-08 WO PCT/US2019/055125 patent/WO2020076775A1/fr active Application Filing
- 2019-10-08 AU AU2019359204A patent/AU2019359204A1/en active Pending
-
2021
- 2021-04-04 IL IL282043A patent/IL282043A/en unknown
- 2021-04-06 CL CL2021000855A patent/CL2021000855A1/es unknown
- 2021-04-06 PH PH12021550759A patent/PH12021550759A1/en unknown
- 2021-05-19 CO CONC2021/0006453A patent/CO2021006453A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021006453A2 (es) | 2021-05-31 |
KR20210074314A (ko) | 2021-06-21 |
EA202190907A1 (ru) | 2021-06-25 |
JP2022512625A (ja) | 2022-02-07 |
US20200109178A1 (en) | 2020-04-09 |
WO2020076775A1 (fr) | 2020-04-16 |
CN113227122A (zh) | 2021-08-06 |
MX2021004032A (es) | 2021-07-06 |
CL2021000855A1 (es) | 2021-11-26 |
PH12021550759A1 (en) | 2021-12-13 |
CA3115480A1 (fr) | 2020-04-16 |
BR112021006614A2 (pt) | 2021-07-20 |
AU2019359204A1 (en) | 2021-04-29 |
SG11202103167VA (en) | 2021-04-29 |
IL282043A (en) | 2021-05-31 |
EP3864027A1 (fr) | 2021-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53858A (fr) | Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques | |
MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
MA50557A (fr) | Pistons pour dispositifs d'administration de médicament | |
MA50751A (fr) | Vaccins à base d'arnm efficaces | |
IL283840A (en) | Preparations for administering therapeutic substances and methods for their use and preparation | |
PH12019500579A1 (en) | Pharmaceutical composition | |
MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA53375A (fr) | Dispositifs d'administration pour l'administration de médicaments | |
MA52154A (fr) | Composition pharmaceutique pour l'anémie | |
MA49393A (fr) | Poly(phosphoesters) destinés à l'administration d'acides nucléiques | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
MA50047A (fr) | Administration orale d'analogues peptidiques de glp-1 | |
MA54139A (fr) | Formulation d'anticorps | |
MA55033A (fr) | Formulation d'anticorps thérapeutique | |
JOP20190040A1 (ar) | توليفة من ناهضات fxr | |
MX2020008076A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
MA49259A (fr) | Anticorps thérapeutiques à base d'hexamères d'igg mutées | |
IL276311A (en) | Methyllactam ring compound and its pharmaceutical use | |
MX2021010022A (es) | Composicion farmaceutica. | |
GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
MA53227A (fr) | Mécanisme d'activation pour dispositif d'administration de médicament | |
MA52148A (fr) | Peptides chimères pour administration d'antisens | |
IL282999A (en) | 4,3,1-oxadiazolone compound and drug | |
MA53009A (fr) | Agents inhibiteurs d'ask1 | |
MA54373A (fr) | Formulation d'administration de médicament au côlon |